ReviewDrug delivery2026
Hydrogel-Based intraperitoneal drug delivery platforms for peritoneal metastasis: strategies, advances, and prospects.
Review in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Natural products targeting cytokine-regulated SASP inflammation networks in Ovarian cancer: Implications on immune escape and molecular resistance.Inflammopharmacology · 2026Review
- High-Resolution 3D Bioprinted Hydrogel Scaffolds Enable Sustained Intraperitoneal Cell Delivery.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal metastasis (PM), as a terminal stage of malignant tumors with extremely poor prognosis, remains a clinical challenge. Intraperitoneal (IP) administration enhances local drug concentrations, improving survival outcomes for PM patients. However, rapid drug clearance and uneven distribution limit its therapeutic potential. In recent years, hydrogel-based drug delivery systems have garnered attention due to their excellent biocompatibility, drug loading capacity, and controlled release properties. The use of hydrogel-loaded drugs via IP injection can significantly improve anti-cancer efficacy by increasing the local drug concentration, prolonging the retention time of the drug in the peritoneal cavity, and decreasing systemic toxicity. This review summarizes the pathogenesis and current treatment strategies of PM, emphasizing various drugs (including chemotherapy agents, immunotherapeutics, targeted drugs, radioactive isotopes, and herbal medicines) delivered via hydrogel-based IP administration. Furthermore, it highlights the potential of nanoparticles and microparticle-hydrogel composites to further improve drug delivery, offering new strategies for PM treatment and theoretical basis for clinical rational drug use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.